OncoMatch/Clinical Trials/NCT07106827
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Is NCT07106827 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies GV20-0251 for hcc - hepatocellular carcinoma.
Treatment: GV20-0251 — This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Melanoma
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Head and Neck Squamous Cell Carcinoma
Endometrial Cancer
Testicular Germ Cell Tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Refractory or intolerant to standard therapies, must have received the standard of care therapy
Cannot have received: anticancer therapy
Exception: allowed if >4 weeks or >5 half-lives before first dose of GV20-0251
Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.
Cannot have received: radiation therapy
Exception: allowed if >14 days before C1D1 dosing
Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07106827 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anticancer therapy, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify